PAREXEL’s Head of Learning and Development Named to 2015 Pharmavoice 100 Most Inspiring People in the Life Sciences List
BOSTON, September 23, 2015 — PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, announced that PharmaVOICE named Albert Siu, PhD, Vice President, Learning and Development, PAREXEL, one of 2015’s PharmaVOICE 100 Most Inspiring People in the Life Sciences Industry. The honor, announced in the July/August 2015 issue of PharmaVOICE magazine, recognizes Dr. Siu’s leadership in developing PAREXEL’s employees and in helping train the next generation of clinical researchers for the industry.
At PAREXEL, Dr. Siu leads professional development, management and leadership, and functional training for more than 18,000 global employees. From traditional instructor-led settings to eLearning environments, Siu’s team at PAREXEL provides best-in-class learning products and customized training programs to present employees with valuable career and job skills development.
Siu also oversees the global PAREXEL Academy, an externally focused clinical and regulatory training organization and degree granting institution with programs tailored to enable clinical research management practices for learners inside and outside of PAREXEL.
“Our commitment to our clients starts with a well-trained workforce. Every day, Albert Siu brings his innovative thinking to PAREXEL and the PAREXEL Academy, representing and ensuring this commitment. In the highly complex and regulated drug development environment, having expertly trained employees around the globe is essential to help our clients simplify their drug development journey,” said Josef von Rickenbach, Chairman and CEO, PAREXEL.
The annual PharmaVOICE 100list honors leaders in the life sciences who positively impact their peers, their colleagues, their companies, their communities, as well as the industry at large through their actions. To read the 2015 PharmaVOICE profiles, visit www.pharmavoice.com.
About PAREXEL International
PAREXEL International Corporation is a leading global biopharmaceutical services organization, providing a broad range of expertise-based contract research, consulting, medical communications, and technology solutions and services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. PAREXEL Informatics provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL has offices in 80 locations in 51 countries around the world, and had approximately 18,660 employees in the fourth quarter. For more information about PAREXEL International visit www.PAREXEL.com
PAREXEL and PAREXEL Informatics are trademarks or registered trademarks of PAREXEL International Corporation or its affiliates.
This release contains “forward-looking” statements regarding future results and events, including, without limitation, statements regarding expected financial results, future growth and customer demand. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words “believes,” “anticipates,” “plans,” “expects,” “intends,” “appears,” “estimates,” “projects,” “will,” “would,” “could,” “should,” “targets,” and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. The Company’s actual future results may differ materially from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from restructurings, including expense savings from the $30 – $45 million restructuring charge disclosed in the press release dated June 23, 2015; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company’s recognition of revenue included in backlog; the Company’s dependence on certain industries and clients; the Company’s ability to win new business, manage growth and costs, and attract and retain employees; the Company’s ability to complete additional acquisitions, and to integrate newly acquired businesses including the acquisitions of ClinIntel Limited and Quantum Solutions India, or enter into new lines of business; the impact on the Company’s business of government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of foreign currency exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled “Risk Factors” of the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2015 as filed with the Securities and Exchange Commission on August 25, 2015, which “Risk Factors” discussion is incorporated by reference in this press release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company’s estimates or views as of any date subsequent to the date of this press release.